POM-V Prescription Required

UBAC Emulsion for Injection for Cattle

Active ingredient: Biofilm Adhesion Component (BAC) of Streptococcus uberis

Form

Injection

Species

Cattle

Manufacturer

Laboratorios Hipra SA

VMD MA No.

EU/2/18/227/001-004

What it's used for

For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce t...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Biofilm Adhesion Component (...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

UBAC Emulsion for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunisation of healthy cows and heifers to reduce the incidence of
clinical intramammary infections caused by Streptococcus uberis, to reduce the
somatic cell count in Streptococcus uberis positive quarter milk samples and to
reduce milk production losses caused by Streptococcus uberis intramammary
infections.
Onset of immunity: approximately 36 days after the second dose.
Duration of immunity: approximately the first 5 months of lactation.

Intramuscular use. The injections should be preferably administered on the alternate
sides of the neck. Allow the vaccine to reach a temperature of +15 to + 25 
administration. Shake before use.
Administer one dose (2 ml) by deep intramuscular injection in the neck muscles
according to the following immunisation program:
- First dose at approximately 60 days before the expected parturition date
- Second dose at least 21 days before the expected parturition date
- Third dose should be administered about 15 days after the calving.
Protection of animals not vaccinated following this program has not been
demonstrated. This should be considered in case of herd vaccination.
The full immunisation program should be repeated with each gestation.

None.

Unlimited Renewal: January 2023
AN: 03163/2022

Local swelling more than 5 cm in diameter at the injection site is a very common
reaction after administration of the vaccine. This swelling will have disappeared or be
clearly reduced in size by 17 days post vaccination. However, in some cases,
swelling may persist for up to 4 weeks.
A transient increase in rectal temperature (mean increase of 1 °C but may be up to 2
°C in individual animals) may very commonly occur in the first 24 hours after
injection.
Anaphylactic-type reactions (e.g. oedema) which might be life-threatening, may occur
very rarely in some sensitive animals based on post-marketing safety experience.

Unlimited Renewal: January 2023
AN: 03163/2022
Under these circumstances, appropriate symptomatic treatment should be
administered.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Vaccinate healthy animals only.
The whole herd should be immunised.
Immunisation has to be considered as one component in a complex intramammary
infection control program that addresses all important udder health factors (e.g.
milking technique, dry-off and breeding management, hygiene, nutrition, housing,
bedding, cow comfort, air and water quality and health monitoring) and other
management practices.

Special precautions for use in animals
Vaccinate only healthy animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-
injection may result in severe pain and swelling, particularly if injected into a joint or
finger, and in rare cases could result in the loss of the affected finger if prompt
medical attention is not given.
If you are accidentally injected with this veterinary medicinal product, seek prompt
medical advice even if only a very small amount is injected and take the package
leaflet with you.
If pain persists for more than 12 hours after medical examination, seek medical
advice again.
To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have
been injected, accidental injection with this product can cause intense swelling, which
may, for example, result in ischaemic necrosis and even the loss of a digit. Expert,
PROMPT, surgical attention is required and may necessitate early incision and
irrigation of the injected area, especially where there is involvement of finger pulp or
tendon.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 ºC – 8 C) and protected from light.
Do not freeze.

Zero days.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for bovidae, inactivated bacterial
vaccines for cattle.
ATCvet code: QI02AB.

Unlimited Renewal: January 2023
AN: 03163/2022
Subunit vaccine to stimulate active immunity against Streptococcus uberis.
In a multicentre field study, the incidence of new cases of Streptococcus uberis
clinical intramammary infection in the group vaccinated with UBAC was 50% lower
than the incidence in the placebo group (

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.